Latest Articles
ARNTL-mediated INO80-DHX15 axis reprograms the glycolytic metabolism and augments the progression of endometrial carcinoma - Nature
ARNTL-mediated INO80-DHX15 axis reprograms the glycolytic metabolism and augments the progression of endometrial carcinoma Nature
Published: June 20, 2025, 8:06 p.m.
Cyclin D2 --a potential biomarker in uterine corpus endometrial carcinoma through methylation chip and bioinformatic analysis - Frontiers
Cyclin D2 --a potential biomarker in uterine corpus endometrial carcinoma through methylation chip and bioinformatic analysis Frontiers
Published: June 19, 2025, 10:09 p.m.
Integrating Deep Learning and Clinical Characteristics for Early Prediction of Endometrial Cancer Using Multimodal Ultrasound Imaging: A Multicenter Study - Frontiers
Integrating Deep Learning and Clinical Characteristics for Early Prediction of Endometrial Cancer Using Multimodal Ultrasound Imaging: A Multicenter Study Frontiers
Published: June 19, 2025, 2:09 p.m.
1st patient dosed in trial of Enhertu for HER2 endometrial cancer - Rare Cancer News
1st patient dosed in trial of Enhertu for HER2 endometrial cancer Rare Cancer News
Published: June 18, 2025, 4:01 p.m.
Endometrial Cancer Treatment Market Overview With Key USA Updates and Global Outlook - openPR.com
Endometrial Cancer Treatment Market Overview With Key USA Updates and Global Outlook openPR.com
Published: June 18, 2025, 7:49 a.m.
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer - MSN
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer MSN
Published: June 16, 2025, 11:46 a.m.
Corrigendum: Loss of CDYL Results in Suppression of CTNNB1 and Decreased Endometrial Receptivity - Frontiers
Corrigendum: Loss of CDYL Results in Suppression of CTNNB1 and Decreased Endometrial Receptivity Frontiers
Published: June 16, 2025, 9:30 a.m.
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer - Insider Monkey
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer Insider Monkey
Published: June 15, 2025, 9:42 a.m.
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer - Yahoo
AstraZeneca’s ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer Yahoo
Published: June 15, 2025, 9:39 a.m.
Multi-Omics Analysis of the Anti-Cancer Effects of Curcumol in Endometrial Carcinoma - Frontiers
Multi-Omics Analysis of the Anti-Cancer Effects of Curcumol in Endometrial Carcinoma Frontiers
Published: June 13, 2025, 5:14 a.m.
Link copied to clipboard!